Health Care & Life Sciences » Biotechnology | Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. | Ownership

Companies that own Fennec Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Southpoint Capital Advisors LP
3,997,214
21.11%
0
1.51%
09/11/2017
venBio Select Advisor LLC
1,022,666
5.4%
1,022,666
0.33%
12/31/2017
Opaleye Management, Inc.
925,000
4.88%
925,000
2.22%
06/13/2018
683 Capital Management LLC
867,185
4.58%
0
0.94%
06/30/2018
Manchester Management Co. LLC
759,584
4.01%
-279,113
22.87%
09/06/2018
Eventide Asset Management LLC
741,175
3.92%
0
0.27%
06/29/2018
Varana Capital LLC
586,945
3.1%
586,945
100%
05/17/2017
BlackRock Fund Advisors
500,195
2.64%
500,195
0%
06/30/2018
Putnam Investment Management LLC
263,433
1.39%
0
0.01%
06/30/2018
Acuta Capital Partners LLC
250,000
1.32%
0
0.42%
06/30/2018

About Fennec Pharmaceuticals

View Profile
Address
Research Triangle Park
Durham North Carolina 27709
United States
Employees -
Website http://www.fennecpharma.com
Updated 07/08/2019
Fennec Pharmaceuticals, Inc. is a small stage biotechnology company, which engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.